Starpharma is an ASX-listed biopharmaceutical company, with an antiviral nasal spray is registered for sale in more than 30 countries around the world. However, it’s still waiting on approval by the TGA here in Australia.

Sean Aylmer talks to Starpharma CEO Dr Jackie Fairley about the long and expensive process of testing and gaining approvals for new medicines, and the exciting technology that underpins Starpharma.

This is general information only. You should seek professional advice before making investment decisions.